Wegovy 2.4mg Results: What the Clinical Evidence Actually Shows

What STEP 1 actually measured at 2.4mg

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with a BMI of 30 or above (or 27 and above with at least one weight-related condition) to either 2.4mg semaglutide weekly or placebo, alongside lifestyle support. Over 68 weeks, the semaglutide group lost an average of around 15% of their starting body weight; the placebo group lost roughly 2.4%. About 69% of those on semaglutide lost at least 10%, and around 32% lost at least 20%. These are averages across a large population. Some participants lost considerably more, others considerably less; individual biology, baseline weight, diet quality and activity levels all pulled results in different directions. The trials were also conducted with close nutritional and behavioural support, conditions that don't perfectly mirror taking a weekly injection alongside ordinary life. Quoting the trial figures is fair and accurate; treating them as a personal forecast is not. For a clear picture of how Wegovy is titrated to get to this dose, our guide to the full Wegovy dose schedule covers each step in plain terms.

How 2.4mg compares with earlier doses in the titration

Wegovy is not started at 2.4mg. The licensed schedule runs 0.25mg, then 0.5mg, then 1mg, then 1.7mg, then 2.4mg, roughly four weeks at each level. Each earlier dose contributes some weight loss while letting the body adjust to the medicine. The bulk of the efficacy data, however, is anchored at 2.4mg, which is why this is the figure most discussed in both NICE's appraisal of semaglutide (published as NICE TA875) and in clinical conversations about what to expect. If you want a sense of how results typically look at the 1mg rung of the ladder, the 1mg Wegovy results page addresses that directly. Reaching 2.4mg takes most people around four months, by which point some have already lost a meaningful amount of weight through the earlier doses, and if you're curious what those early weeks tend to look like you can read about 0.25mg Wegovy results and then see how things typically progress when you move up to the 0.5mg dose. That staged build is deliberate: it reduces the risk of nausea and other GI effects rather than front-loading the dose for faster loss.

Where 2.4mg sits in light of newer evidence

When the MHRA approved the 7.2mg Wegovy dose (and later a dedicated single-dose 7.2mg pen, on 14 April 2026), it shifted how clinicians and patients think about the ceiling of semaglutide's effect. Trial data for 7.2mg showed average weight loss of around 20.7% over 72 weeks, narrowing the gap with the tirzepatide results seen in SURMOUNT-1. For most people currently on Wegovy in the UK, however, 2.4mg is still the working maintenance dose, and the one against which treatment adequacy is generally judged. NICE's recommendation under TA875 notes that if fewer than 5% of body weight is lost after six months on the maintenance dose, continuing treatment should be reviewed. Worth knowing if you're approaching that checkpoint. The Wegovy overview page covers how the medicine fits into the broader UK treatment landscape, including what the NHS pathway looks like in practice.

What the numbers don't tell you, and when to raise it with a prescriber

Clinical trial participants are selected, monitored closely, and supported in ways that everyday patients often aren't. That doesn't make the evidence less real; it does make interpretation important. A question our prescribers hear regularly is whether a slower-than-expected result at 2.4mg means the medicine isn't working, or whether something (missed doses, GI side effects reducing appetite less than expected, an underlying condition) is worth investigating. No content page can answer that for you, and this one won't try. The right conversation is with the clinician managing your treatment. If you're thinking about how results at 1.7mg compare before stepping up, that's a reasonable question to bring to a review. Most common side effects at 2.4mg are gastrointestinal (nausea, loose stools, constipation and reflux feature most often) and are usually worst after dose increases, settling within a couple of weeks for most people. If you'd like to understand the full range of weight-loss treatment options available through a UK-regulated service, including how Wegovy compares with other licensed medicines, that's a good starting point before a consultation. Check your eligibility with our prescribers to see whether Wegovy at 2.4mg (or any maintenance dose) makes clinical sense for you.